- Home
- CHRS vs TDUP Comparison
CHRS vs TDUP Comparison
Compare CHRS & TDUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- TDUP
- Stock Information
- Founded
- CHRS 2010
- TDUP 2009
- Country
- CHRS United States
- TDUP United States
- Employees
- CHRS N/A
- TDUP N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- TDUP Catalog/Specialty Distribution
- Sector
- CHRS Health Care
- TDUP Consumer Discretionary
- Exchange
- CHRS Nasdaq
- TDUP Nasdaq
- Market Cap
- CHRS 191.3M
- TDUP 172.9M
- IPO Year
- CHRS 2014
- TDUP 2021
- Fundamental
- Price
- CHRS $1.46
- TDUP $1.27
- Analyst Decision
- CHRS Strong Buy
- TDUP Buy
- Analyst Count
- CHRS 4
- TDUP 5
- Target Price
- CHRS $5.38
- TDUP $3.50
- AVG Volume (30 Days)
- CHRS 2.3M
- TDUP 426.6K
- Earning Date
- CHRS 11-06-2024
- TDUP 03-03-2025
- Dividend Yield
- CHRS N/A
- TDUP N/A
- EPS Growth
- CHRS N/A
- TDUP N/A
- EPS
- CHRS N/A
- TDUP N/A
- Revenue
- CHRS $304,340,000.00
- TDUP $313,757,000.00
- Revenue This Year
- CHRS $2.47
- TDUP N/A
- Revenue Next Year
- CHRS N/A
- TDUP N/A
- P/E Ratio
- CHRS N/A
- TDUP N/A
- Revenue Growth
- CHRS 44.19
- TDUP 0.58
- 52 Week Low
- CHRS $0.66
- TDUP $0.50
- 52 Week High
- CHRS $2.97
- TDUP $2.42
- Technical
- Relative Strength Index (RSI)
- CHRS 49.75
- TDUP 40.56
- Support Level
- CHRS $1.35
- TDUP $1.30
- Resistance Level
- CHRS $1.77
- TDUP $1.59
- Average True Range (ATR)
- CHRS 0.13
- TDUP 0.11
- MACD
- CHRS -0.02
- TDUP -0.04
- Stochastic Oscillator
- CHRS 25.00
- TDUP 7.89
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.